KRAS and pachyonychia congenita: As is known, the development of PC is a process characterized by the accumulation of gene mutations, and the accompanying aberrant genetic events are generally observed in oncogene KRAS (activation) and tumor suppressors TP53, CDKN2A and SMAD4 (inactivation) [52].